Latest Financial Results
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2024
Report Links
Company Overview
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of pulmonary arterial hypertension (PAH).